Medindia

X

3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009

Friday, September 18, 2009 General News J E 4
Advertisement
SHENYANG, China, July 23 3SBio Inc.(Nasdaq: SSRX), a leading China-based biotechnology company focused onresearching, developing, manufacturing and marketing biopharmaceuticalproducts, today announced that it will release financial results for thesecond quarter ended June 30, 2009 after the US market closes on Tuesday,August 11, 2009.

Following the earnings announcement, 3SBio's senior management will host aconference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 8:00 pm(Beijing/Hong Kong) on Wednesday, August 12, 2009 to discuss its 2009 secondquarter financial results and recent business activity. The conference callmay be accessed using the dial-in numbers below:

Replay

A telephone replay will be available two hours after the call until August17, 2009, at:

Webcast

A live webcast of the conference will be available on the investorrelations page of 3SBio's website athttp://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/l8hs96. A replay of the webcast will be available within one hour after theconclusion of the call.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused onresearching, developing, manufacturing and marketing biopharmaceuticalproducts, primarily in China. For more information, please visit 3SBio on theweb at http://www.3sbio.com or contact us at ir@3SBio.com.

Safe Harbor Statement

Statements in this release may contain "forward-looking" statements withinthe meaning of Section 27A of the Securities Act of 1933, as amended, andSection 21E of the Securities Exchange Act of 1934, as amended, and as definedin the Private Securities Litigation Reform Act of 1995. These statements arebased upon 3SBio management's current expectations, and actual results coulddiffer materially. Among the factors that could cause 3SBio's actual resultsto differ from what the company currently anticipates may include competitionfrom other domestic and foreign pharmaceutical companies; the expected marketgrowth for pharmaceutical products in China; market acceptance of 3SBioproducts; expected hospital or patient demand for our products; the completionof 3SBio's ongoing clinical trials as planned; receipt and timing ofregulatory approvals for 3SBio's new products and uses; 3SBio's ability toexpand its production, sales and distribution network and other aspects of itsoperations; its ability to effectively protect its intellectual property;changes in the healthcare industry in China, including changes in thehealthcare policies and regulations of the PRC government and changes in thehealthcare insurance sector in the PRC; and fluctuations in general economicand business conditions in China. For additional information on these andother factors that may affect the 3SBio's financial results, please refer tothe company's filings with the Securities and Exchange Commission atwww.sec.gov. 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events orotherwise, after the date of this press release.Conference ID: 21352657 Local dial-in: China - landline 800-819-0121 China - mobile 400-620-8038 International toll-free dial-in: Hong Kong 800933053 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65-6735-7955

SOURCE 3SBio Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Digirad Corporation Reports Second Quarter 2009 Fi...
S
Misys - Preliminary Results Interview With CEO